Floatz logo

DACETUZUMAB

Lymphoma, Large B-Cell, Diffuse

Seagen Inc.monoclonal_antibodyPhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

271 Active assets in the Lymphoma, Large B-Cell, Diffuse cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

DACETUZUMAB is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
58 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →